Dupilumab  (Synonyms: 杜匹鲁单抗; REGN-668; SAR-231893)

Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

Dupilumab 抑制与皮肤损伤中 T 细胞、DC、嗜酸性粒细胞、炎症通路和 TH2 诱导趋化因子激活相关的基因的 mRNA 表达。未检测到 IL-17A 或 IL-22 水平显著降低，但 IL-17 相关基因的表达大幅降低，例如弹性蛋白 (PI3)、IL23p19/IL23A 和 S100A8 以及抑制趋势 (CXCL1 和 S100A7) 在 300 mg Dupilumab 中发现^[1]。
增生相关基因 (例如 K16) 的主要抑制和 S100A 基因表达的减少在 300 mg Dupilumab 中是明显的，通过使用微阵列和 qRT-PCR。还测量了严重特应性皮炎 (AD) 皮肤中其他关键表皮改变的变化，包括使用 300 mg Dupilumab 时密蛋白和脂质产物水平的显著增加。在调整抑制表皮增生后，观察到分化基因 (LOR 和 FLG) 表达呈剂量依赖性增加的趋势，如 Dupilumab的 K16 减少所证明的^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1190264-60-8

液体

Colorless to light yellow

度普利尤单抗； 达必妥

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Flow cytometry analysis of Raji cells labelling IL-4Rα with Dupilumab at 100nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

• [1]. Hamilton JD, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300.  [Content Brief]